Targeting IRAK4 in Chronic Lymphocytic Leukemia
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Peripheral blood sample collection.
- Who it may be relevant to
- Registry conditions: Chronic Lymphocytic Leukemia (CLL). Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Patients with chronic lymphocytic leukemia (CLL) followed at Strategic Research Program on CLL will be enrolled and undergo sampling of additional amount of blood at the time of standard blood tests. Leukemic B cells and peripheral blood mononuclear cells (PBMC).
Detailed description
Patients with chronic lymphocytic leukemia (CLL) followed at Strategic Research Program on CLL will be enrolled and undergo sampling of additional amount of blood at the time of standard blood tests. Leukemic B cells and peripheral blood mononuclear cells (PBMC). Up to 50 ml of blood will be collected for the research project at the time of standard blood tests.
Interventions
- Procedure Peripheral blood sample collection
Up to 50 ml of blood will be collected for the research project at the time of standard blood tests.
Primary outcome measures
- TLR signaling [Time frame: 12 months]
Eligibility criteria
Inclusion criteria
- Age ≥18 years
- Diagnosis of CLL
- Participant is willing and able to give informed consent for participation in the study.
Exclusion criteria
\- Participant is unable or unwilling to provide informed consent for participation in the study
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Publications
- Delvecchio VS, Sana I, Mantione ME, Vilia MG, Ranghetti P, Rovida A, Angelillo P, Scarfo L, Ghia P, Muzio M. Interleukin-1 receptor-associated kinase 4 inhibitor interrupts toll-like receptor signalling and sensitizes chronic lymphocytic leukaemia cells to apoptosis. Br J Haematol. 2020 May;189(3):475-488. doi: 10.1111/bjh.16386. Epub 2020 Feb 14. PMID 32057093
Identifiers
NCT: NCT07741695 · PS-CLL016